Ensign Peak Advisors Inc Sells 10,200 Shares of Bath & Body Works, Inc. $BBWI

Ensign Peak Advisors Inc cut its stake in Bath & Body Works, Inc. (NYSE:BBWI) by 15.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,929 shares of the company’s stock after selling 10,200 shares during the period. Ensign Peak Advisors Inc’s holdings in Bath & Body Works were worth $1,706,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Bath & Body Works in the 2nd quarter valued at $33,000. SVB Wealth LLC acquired a new position in shares of Bath & Body Works in the 1st quarter worth approximately $35,000. Geneos Wealth Management Inc. boosted its position in Bath & Body Works by 217.7% during the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after acquiring an additional 801 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Bath & Body Works by 63.3% during the 2nd quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock valued at $37,000 after purchasing an additional 481 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in Bath & Body Works by 24.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,842 shares of the company’s stock worth $55,000 after purchasing an additional 364 shares in the last quarter. 95.14% of the stock is owned by institutional investors.

Bath & Body Works Trading Up 2.9%

Bath & Body Works stock opened at $17.40 on Friday. Bath & Body Works, Inc. has a 1-year low of $14.27 and a 1-year high of $41.87. The firm has a market cap of $3.56 billion, a P/E ratio of 5.16, a P/E/G ratio of 0.86 and a beta of 1.53. The firm has a 50-day moving average of $23.84 and a 200-day moving average of $27.75.

Bath & Body Works (NYSE:BBWI) last posted its earnings results on Thursday, November 20th. The company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.05). Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Bath & Body Works has set its FY 2025 guidance at 2.870- EPS. Q4 2025 guidance at 1.700- EPS. Research analysts forecast that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.

Bath & Body Works Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Friday, November 21st will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend is Friday, November 21st. Bath & Body Works’s dividend payout ratio is currently 24.62%.

Insider Buying and Selling

In other news, Director Steven E. Voskuil acquired 20,000 shares of Bath & Body Works stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $15.04 per share, for a total transaction of $300,800.00. Following the purchase, the director owned 33,925 shares in the company, valued at $510,232. This trade represents a 143.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francis Hondal acquired 3,343 shares of Bath & Body Works stock in a transaction that occurred on Friday, November 21st. The stock was acquired at an average price of $14.99 per share, with a total value of $50,111.57. Following the completion of the acquisition, the director directly owned 21,554 shares in the company, valued at $323,094.46. This represents a 18.36% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 33,513 shares of company stock valued at $500,442 over the last ninety days. Insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BBWI shares. Citigroup cut their price target on Bath & Body Works from $35.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Barclays cut their price objective on shares of Bath & Body Works from $28.00 to $18.00 and set an “equal weight” rating on the stock in a report on Friday, November 21st. Morgan Stanley reaffirmed an “equal weight” rating and set a $18.00 price target (down from $43.00) on shares of Bath & Body Works in a research report on Friday, November 21st. New Street Research set a $26.00 price objective on shares of Bath & Body Works in a report on Monday. Finally, Robert W. Baird restated a “neutral” rating and issued a $19.00 target price (down from $33.00) on shares of Bath & Body Works in a research note on Thursday, November 20th. Six investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.17.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.